The Phoenix Mills Ltd. (PDF)
Trending Sector
Top Losers
Current IPOs
Closed IPOs
Listed IPOs
IPO Performers
CAGR Calculator
SIP Calculator
Retirement Planning Calculator
Adani Ports and SEZ
Onyx Biotec Ltd IPO
Status: Closed
Overview
IPO date
13 Nov 2024 to 18 Nov 2024
Face value
₹ 10 per share
Price
₹ 58 to ₹61 per share
Issue Size
4,810,000 shares
(aggregating up to ₹ 29.34 Cr)
(aggregating up to ₹ 29.34 Cr)
Allotment Date
19 Nov 2024
Listing at
NSE
Issue type
Book Building - SME
Sector
Pharmaceuticals
Objectives of Onyx Biotec Ltd IPO
Initial public offer of upto 48,10,000 equity shares of face value of
Rs. 10/- each ("Equity Shares") of the company at an issue price of Rs. 61 per equity share (including a share premium of Rs. 51 per equity share) for cash, aggregating up to Rs. 29.34 crores ("Public Issue") out of which 2,44,000 equity shares of face value of Rs. 10/- each, at an issue price of Rs. 61 per equity share for cash, aggregating Rs. 1.49 crores will be reserved for subscription by the market maker to the issue (the "Market Maker Reservation Portion"). The public issue less market maker reservation portion i.e. issue of 45,66,000 equity shares of face value of Rs. 10/- each, at an issue price of Rs. 61 per equity share for cash, aggregating up to Rs. 27.85 crores is hereinafter referred to as the "Net Issue". The public issue and net issue will constitute 26.53 % and 25.18 % respectively of the post-issue paid-up equity share capital of the company.
Onyx Biotec Ltd IPO Strategy
- Market Penetration and Geographic Expansion.
- Leverage our position as a contract manufacturer for pharmaceutical companies.
- Leverage our position in the loan licencing to the pharma companies.
- Focus on our Quality Control.
- Growing our business with existing clients with quality products.
- Reduction of operational costs and achieving efficiency.
About Onyx Biotec Ltd
Onyx Biotec Limited was incorporated as Onyx Biotec Private Limited', pursuant to a Certificate of Incorporation dated May 13, 2005 issued by the Registrar of Companies, Punjab, H.P. & Chandigarh. Further, Company converted into a Public Limited and the name was changed to Onyx Biotec Limited' and a fresh Certificate of Incorporation dated July 23, 2024 was issued by the Registrar of Companies, Central Processing Centre.
Onyx started its operation in pharmaceutical industry with sterile water for injections with capacity of 2 lacs units per day in year 2010. Since then, Onyx is engaged in Manufacturing of Pharmaceutical Products such as sterile water ampoule, dry injection, dry syrup etc. to major corporations, which includes the top pharma companies.
Presently, the Company manufactures Sterile Water for Injections, and acts as a pharmaceutical contract manufacturer offering a comprehensive range of Dry Powder Injections and Dry Syrup for India and overseas. The core business is on providing end-to-end product development and manufacturing solutions to clients. The service include preparation and filing of regulatory dossiers in the Indian and global markets.
The Company has Unit I and Unit II manufacturing plants in Solan District of Himachal Pradesh. The facility Unit I is having production capacity of 6,38,889 units of Sterile Water for Injections per day and Unit II is having a capacity of 40,000 units of dry Powder injection per day and 26,667 units of dry syrup per day in a single shift.
The Company later on, enhanced the capacity expansion from 130 million unit per annum to 230 million units per annum capacity in 2017-18. Further, the Company commenced their Unit II commercial production in 2023.
Company is planning an IPO of 48,10,000 Fresh Issue Equity Shares.
Unlock Stock of the Month
T&C*
Strengths vs Risks of Onyx Biotec Ltd
Know the pros & cons
Strengths
One of the prominent contract manufacturers in sterile manufacturing.- Quality Assurance and Quality Control of our products.
- Strong, cordial & long-term relationship with our Marque Clientele.
- Cost effective production and timely fulfilment of orders.
- Well experienced management team with proven project management and implementation skills.
Risks
- Its manufacturing units are concentrated in Solan, Himachal Pradesh, and the company is exposed to risks originating from economic, regulatory, political and other changes in this region, including natural disasters, which could adversely affect its business, results of operations and financial condition.
- Any slowdown or shutdown in its manufacturing operations could have an adverse effect on its business, results of operations, financial condition and cash flows.
- Any manufacturing or quality control concerns or its inability to deliver products on a timely basis, or at all, could result in the cancellation of purchase orders, breaches of relevant agreements, and termination of agreements by its clients and distributors, which could have an adverse effect on its business, results of operations, financial condition and cash flows.
- Its manufacturing units are subject to periodic inspections and audits by regulatory authorities and clients. The company may be subject to regulatory action which may damage its reputation leading to an adverse effect on its business, results of operations, financial condition and cash flows.
- The company relies on domestic and international third-party suppliers for the supply of raw materials and any delay, interruption or reduction in such supply could adversely affect its business, results of operations, financial condition and cash flows.
- Its business is dependent on sale of products to a limited number of clients for a significant portion of its revenues. The loss of one or more such clients or the deterioration of their financial condition or prospects could adversely affect its business, results of operations and financial condition.
- The Company is reliant on the demand from the pharmaceutical industry. Any downturn in the pharmaceutical industry or an inability to increase or effectively manage its sales could have an adverse impact on the Company's business and results of operations.
- The commercial success of its products depends to a large extent on the success of the products of its customers. If the demand for the products of the company's customers declines, it could have a material adverse effect on its business, financial condition and results of operations.
- Its may faces several risks associated with the proposed expansion of the company's manufacturing facilities, which could hamper its growth, prospects, cash flows and business and financial condition.
- Its cannot assure you that the proposed expansion of the company's manufacturing units will become operational as scheduled, or at all, or operates as efficiently as planned. If the company is unable to commission its new facilities in a timely manner or without cost overruns, it may adversely affect its business, results of operations and financial condition.
- Any failures in its quality control processes may adversely affect the company's business, results of operations and financial condition. Its may face product liability claims and legal proceedings if the quality of its products does not meet the company's customers' expectations.
- Any adverse change in regulations governing its products and the products of the company's customers, may adversely impact its business prospects and results of operations.
- There have been instances of delays in payment of statutory dues, i.e. GST by the Company. In case of any delay in payment of statutory due in future by the Company, the Regulatory Authorities may impose monetary penalties on it or take certain punitive actions against the Company in relation to the same which may have adverse impact on its business, financial condition and results of operations.
- There have been instances of delays in filings of certain forms which were required to be filed as per the reporting requirements under the Companies Act, 2013 to ROC.
- If its product development efforts do not succeed, the company may not be able to improve its existing products and/or introduce new products, which could adversely affect its results of operations, growth and prospects. Further, if the company is unable to anticipate and respond to changes in the market trends and changing customer preferences in a timely and effective manner, or if its fails to maintain the company reputation, brand value or increase the market for its products, the demand for the company products may decline.
- The Company is yet to place orders for the plant and machinery for the proposed expansion of its manufacturing units. Any delay in placing orders or procurement of such plant and machinery may delay the schedule of implementation and possibly increase the cost of commissioning the manufacturing unit.
- The cost estimates for the proposed expansion of its manufacturing units have been derived from internal estimates of our management and may not be accurate.
- The company is subject to the risk of loss due to fire, accidents and other hazards as its manufacturing processes utilize materials that are highly flammable and hazardous. Any failures to comply with existing and future regulatory requirements or non-compliance with and changes in, safety, health, environmental and labour laws and other applicable regulations, could adversely affect its business, results of operations, financial condition and cash flows.
- The company operates in a market that is highly competitive to provide outsourced pharmaceutical manufacturing services, particularly for formulations, to clients in India and other jurisdictions.
- Any delays and/or defaults in customer payments could result in increase of working capital investment and/or reduction of the Company's profits, thereby affecting its operation and financial condition.
- Its inability to effectively manage the company's growth or to successfully implement its business plan and growth strategy could adversely affect its business, results of operations and financial condition.
- The Company requires significant amount of working capital for a continuing growth. Its inability to meet the company's working capital requirements may adversely affect its results of operations.
- The company is dependent on information technology systems in carrying out its business activities and it forms an integral part of the company's business. Further, if the company is unable to adapt to technological changes and successfully implement new technologies or if the company faces failures of its information technology systems, its may not be able to compete effectively which may result in higher costs and would adversely affect its business and results of operations.
- The company may be unable to grow its business in additional geographic regions or international markets, which may adversely affect its business prospects and results of operations.
- The company application for certain licenses, approvals and registrations, which are required for the Company's operations and business, are pending before the relevant authorities. Not receiving these licenses, approvals and registrations in a timely manner or at all may lead to interruption of the Company's operations.
- The Company has applied for registration of certain trademarks in its name. Until such registrations are granted, the Company may not be able to prevent unauthorised use of such trademarks by third parties, which may lead to the dilution of it goodwill.
- The Company has issued Equity Shares in the last one year at a price which may be lower that the Issue Price.
- Its may be unable to grow the company's business in additional geographic regions or international markets, which may adversely affect its business prospects and results of operations.
- The Company has experienced negative cash flow in the past and may continue to do so in the future, which could have a material adverse effect on its business, prospects, financial condition, cash flows and results of operations.
- The company is dependent on third party transportation providers for delivery of raw materials to it from its suppliers and delivery of the company finished products to its customers. The company has not entered into any formal contracts with its transport providers and any failure on part of such service providers to meet their obligations could adversely affect its business, financial condition and results of operation.
- The company has significant power requirements for continuous running of its manufacturing units. Any disruption to the company's operations on account of interruption in power supply or any irregular or significant hike in power tariffs may have an effect on its business, results of operations and financial condition.
- The company's Promoters, Directors, Senior Management and Key Managerial Personnel have interests in the Company other than reimbursement of expenses incurred or normal remuneration or benefits.
- Its Promoters, Directors and members of Promoter Group have extended personal guarantees with respect to loan facilities availed by the Company. Further, its Promoters have extended personal properties as collateral for securing the facilities availed by the Company. Revocation of any or all of these personal guarantees or withdrawal of such properties may adversely affect its business operations and financial condition.
- Its Promoters and members of the Promoter Group have significant control over the Company and have the ability to direct its business and affairs; their interests may conflict with your interests as a shareholder.
- The average cost of acquisition of Equity Shares held by its Promoters could be lower than the Issue Price.
- The company's future fund requirements, in the form of further issue of capital or securities and/or loans taken by it, may be prejudicial to the interest of the Shareholders depending upon the terms on which they are eventually raised.
- The company has in past entered into related party transactions and its may continue to do so in the future.
- Its agreements with lenders for financial arrangements contain restrictive covenants for certain activities and if the company is unable to get their approval, it might restrict its scope of activities and impede the company growth plans.
- The Company has availed certain unsecured loans from its Promoters and third parties, which are recallable in nature.
- In addition to its existing indebtedness for the company existing operations, its may incur further indebtedness during the course of business. The company cannot assure that its would be able to service its existing and/ or additional indebtedness.
- The company has not made any alternate arrangements for meeting its capital requirements for the Objects of the Issue. Further, the company has not identified any alternate source of financing the 'objects of the Issue'. Any short fall in raising / meeting the same could adversely affect its growth plans, operations and financial performance.
- If the company is unable to identify customer demand accurately and maintain an optimal level of inventory proportionately, its business, results of operations and financial condition may be adversely affected.
- The company's success largely depends upon the knowledge and experience of its Promoters, Directors and the company Key Managerial Personnel. Loss of any of its Directors and key managerial personnel or the company's ability to attract and retain them could adversely affect its business, operations and financial condition.
- The company's inability to procure and/or maintain adequate insurance cover in connection with its business may adversely affect the company's operations and profitability.
- Its ability to pay dividends in the future may be affected by any material adverse effect on its future earnings, financial condition or cash flows.
- The deployment of funds is entirely at its discretion and as per the details mentioned in the chapter titled "Objects of the Issue".
- The company has not independently verified certain data in this Draft Red Herring Prospectus.
- The requirements of being a listed company may strain its resources.
- Delay in raising funds from the IPO could adversely impact the implementation schedule.
- The Equity Shares have never been publicly traded and the Issue may not result in an active or liquid market for the Equity Shares.
- There is no guarantee that the Equity Shares issued pursuant to the Issue will be listed on the SME Platform of National Stock Exchange of India Limited in a timely manner or at all.
- There is no existing market for its Equity Shares, and the company does not know if one will develop to provide you with adequate liquidity. Further, an active trading market for the Equity Shares may not develop and the price of the Equity Shares may be volatile.
- Any variation in the utilisation of the Net Proceeds or in the terms of any contract as disclosed in the Draft Red Herring Prospectus would be subject to certain compliance requirements, including prior shareholders' approval.
- You will not be able to sell immediately on the Stock Exchanges any of the Equity Shares you purchase in the Issue.
- There are restrictions on daily movements in the trading price of the Equity Shares, which may adversely affect a shareholder's ability to sell Equity Shares or the price at which Equity Shares can be sold at a particular point in time.
- The price of the Equity Shares may be volatile, which could result in substantial losses for investors acquiring the Equity Shares in the Issue.
- Any future issuance of Equity Shares, or convertible securities or other equity-linked securities by the Company may dilute your shareholding and any sale of Equity Shares by its Promoters or members of the company's Promoter Group may adversely affect the trading price of the Equity Shares.
- Rights of shareholders under Indian laws may be more limited than under the laws of other jurisdictions.
Onyx Biotec Ltd Peer Comparison
Understand the company’s industry standing
Onyx Biotec Ltd
Suven Pharmaceuticals Ltd
J B Chemicals & Pharmaceuticals Ltd
Face Value
10
1
1
Standalone / Consolidated
Standalone
Standalone
Standalone
Total Income Rs. Cr.
53.7488
1051.3537
3484.1838
EPS-Basis
2.28
11.8
35.66
EPS-Diluted
2.28
11.8
35.66
NAV Per Share
18.67
375.82
188.37
P/E-Basic EPS
---
83.92
53.63
P/E-Diluted EPS
---
---
---
RONW(%)
12.19
14.64
18.9
Latest NAV Period
---
---
---
Latest NAV
---
---
---
How to check the allotment status of Onyx Biotec Ltd IPO?
Follow the steps
Open link to the registrar using this URL (https://evault.kfintech.com/ipostatus/).
Select company from dropdown menu.
Enter details- PAN, Application number or DP client ID
Get your allotment status
Open link to the registrar using this URL (https://evault.kfintech.com/ipostatus/).
IPO reads
Stay updated with the latest IPO developments
December 9, 2024 | 5 min read
11 IPOs This Week: ₹18,482 Crores in Focus – GMP, SWOT, and All You Need to Know!
December 2, 2024 | 5 min read
Upcoming IPOs in December 2024: A Packed Month for Investors
November 25, 2024 | 5 min read
SME IPO Rush: 6 Issues Worth ₹410 Cr. Know Key Details Here!
October 25, 2024 | 5 min read
Waaree Energies IPO: GMP Soars 106% Amid 76.34x Subscription – Check Your Allotment Status!
October 22, 2024 | 5 min read
Upcoming IPOs: 9 Public Issues Set to Raise ₹10,984.8 Cr – Key Insights Inside!
October 17, 2024 | 5 min read
Hyundai IPO Hits a Speed Bump With 42% Subscription On Day 2 : 4 Reasons Why
September 6, 2024 | 5 min read
Bajaj Housing Finance IPO: All You Need to KnowOctober 17, 2024 | 5 min read
Hyundai IPO Hits a Speed Bump With 42% Subscription On Day 2 : 4 Reasons Why
August 26, 2024 | 5 min read
Premier Energies IPO: Key Details Ahead of the ₹2,830.40 Cr Issue LaunchMore on IPOs
Navigate your way to other IPO resources
Latest videos on IPOs
IPO highlights & details!
FAQs on IPO
Get answers to all your questions here!
The IPO opens on 13 Nov 2024 & closes on 18 Nov 2024.
Onyx Biotec Limited was incorporated as Onyx Biotec Private Limited', pursuant to a Certificate of Incorporation dated May 13, 2005 issued by the Registrar of Companies, Punjab, H.P. & Chandigarh. Further, Company converted into a Public Limited and the name was changed to Onyx Biotec Limited' and a fresh Certificate of Incorporation dated July 23, 2024 was issued by the Registrar of Companies, Central Processing Centre.
Onyx started its operation in pharmaceutical industry with sterile water for injections with capacity of 2 lacs units per day in year 2010. Since then, Onyx is engaged in Manufacturing of Pharmaceutical Products such as sterile water ampoule, dry injection, dry syrup etc. to major corporations, which includes the top pharma companies.
Presently, the Company manufactures Sterile Water for Injections, and acts as a pharmaceutical contract manufacturer offering a comprehensive range of Dry Powder Injections and Dry Syrup for India and overseas. The core business is on providing end-to-end product development and manufacturing solutions to clients. The service include preparation and filing of regulatory dossiers in the Indian and global markets.
The Company has Unit I and Unit II manufacturing plants in Solan District of Himachal Pradesh. The facility Unit I is having production capacity of 6,38,889 units of Sterile Water for Injections per day and Unit II is having a capacity of 40,000 units of dry Powder injection per day and 26,667 units of dry syrup per day in a single shift.
The Company later on, enhanced the capacity expansion from 130 million unit per annum to 230 million units per annum capacity in 2017-18. Further, the Company commenced their Unit II commercial production in 2023.
Company is planning an IPO of 48,10,000 Fresh Issue Equity Shares.
Onyx Biotec Ltd IPO will close on 18 Nov 2024.
- One of the prominent contract manufacturers in sterile manufacturing.
- Quality Assurance and Quality Control of our products.
- Strong, cordial & long-term relationship with our Marque Clientele.
- Cost effective production and timely fulfilment of orders.
- Well experienced management team with proven project management and implementation skills.
| S.No | Promoters Name | Pre Issue Shares | Pre Issue Percentage | Post Issue Shares | Post Issue Percentage |
|---|---|---|---|---|---|
| 1 | Sanjay Jain | 3894600 | 29.23 | 3894600 | 21.48 |
| 2 | Naresh Kumar | 4347000 | 32.63 | 4347000 | 23.97 |
| 3 | Fateh Pal Singh | 3561600 | 26.73 | 3561600 | 19.64 |
- Its manufacturing units are concentrated in Solan, Himachal Pradesh, and the company is exposed to risks originating from economic, regulatory, political and other changes in this region, including natural disasters, which could adversely affect its business, results of operations and financial condition.
- Any slowdown or shutdown in its manufacturing operations could have an adverse effect on its business, results of operations, financial condition and cash flows.
- Any manufacturing or quality control concerns or its inability to deliver products on a timely basis, or at all, could result in the cancellation of purchase orders, breaches of relevant agreements, and termination of agreements by its clients and distributors, which could have an adverse effect on its business, results of operations, financial condition and cash flows.
- Its manufacturing units are subject to periodic inspections and audits by regulatory authorities and clients. The company may be subject to regulatory action which may damage its reputation leading to an adverse effect on its business, results of operations, financial condition and cash flows.
- The company relies on domestic and international third-party suppliers for the supply of raw materials and any delay, interruption or reduction in such supply could adversely affect its business, results of operations, financial condition and cash flows.
- Its business is dependent on sale of products to a limited number of clients for a significant portion of its revenues. The loss of one or more such clients or the deterioration of their financial condition or prospects could adversely affect its business, results of operations and financial condition.
- The Company is reliant on the demand from the pharmaceutical industry. Any downturn in the pharmaceutical industry or an inability to increase or effectively manage its sales could have an adverse impact on the Company's business and results of operations.
- The commercial success of its products depends to a large extent on the success of the products of its customers. If the demand for the products of the company's customers declines, it could have a material adverse effect on its business, financial condition and results of operations.
- Its may faces several risks associated with the proposed expansion of the company's manufacturing facilities, which could hamper its growth, prospects, cash flows and business and financial condition.
- Its cannot assure you that the proposed expansion of the company's manufacturing units will become operational as scheduled, or at all, or operates as efficiently as planned. If the company is unable to commission its new facilities in a timely manner or without cost overruns, it may adversely affect its business, results of operations and financial condition.
- Any failures in its quality control processes may adversely affect the company's business, results of operations and financial condition. Its may face product liability claims and legal proceedings if the quality of its products does not meet the company's customers' expectations.
- Any adverse change in regulations governing its products and the products of the company's customers, may adversely impact its business prospects and results of operations.
- There have been instances of delays in payment of statutory dues, i.e. GST by the Company. In case of any delay in payment of statutory due in future by the Company, the Regulatory Authorities may impose monetary penalties on it or take certain punitive actions against the Company in relation to the same which may have adverse impact on its business, financial condition and results of operations.
- There have been instances of delays in filings of certain forms which were required to be filed as per the reporting requirements under the Companies Act, 2013 to ROC.
- If its product development efforts do not succeed, the company may not be able to improve its existing products and/or introduce new products, which could adversely affect its results of operations, growth and prospects. Further, if the company is unable to anticipate and respond to changes in the market trends and changing customer preferences in a timely and effective manner, or if its fails to maintain the company reputation, brand value or increase the market for its products, the demand for the company products may decline.
- The Company is yet to place orders for the plant and machinery for the proposed expansion of its manufacturing units. Any delay in placing orders or procurement of such plant and machinery may delay the schedule of implementation and possibly increase the cost of commissioning the manufacturing unit.
- The cost estimates for the proposed expansion of its manufacturing units have been derived from internal estimates of our management and may not be accurate.
- The company is subject to the risk of loss due to fire, accidents and other hazards as its manufacturing processes utilize materials that are highly flammable and hazardous. Any failures to comply with existing and future regulatory requirements or non-compliance with and changes in, safety, health, environmental and labour laws and other applicable regulations, could adversely affect its business, results of operations, financial condition and cash flows.
- The company operates in a market that is highly competitive to provide outsourced pharmaceutical manufacturing services, particularly for formulations, to clients in India and other jurisdictions.
- Any delays and/or defaults in customer payments could result in increase of working capital investment and/or reduction of the Company's profits, thereby affecting its operation and financial condition.
- Its inability to effectively manage the company's growth or to successfully implement its business plan and growth strategy could adversely affect its business, results of operations and financial condition.
- The Company requires significant amount of working capital for a continuing growth. Its inability to meet the company's working capital requirements may adversely affect its results of operations.
- The company is dependent on information technology systems in carrying out its business activities and it forms an integral part of the company's business. Further, if the company is unable to adapt to technological changes and successfully implement new technologies or if the company faces failures of its information technology systems, its may not be able to compete effectively which may result in higher costs and would adversely affect its business and results of operations.
- The company may be unable to grow its business in additional geographic regions or international markets, which may adversely affect its business prospects and results of operations.
- The company application for certain licenses, approvals and registrations, which are required for the Company's operations and business, are pending before the relevant authorities. Not receiving these licenses, approvals and registrations in a timely manner or at all may lead to interruption of the Company's operations.
- The Company has applied for registration of certain trademarks in its name. Until such registrations are granted, the Company may not be able to prevent unauthorised use of such trademarks by third parties, which may lead to the dilution of it goodwill.
- The Company has issued Equity Shares in the last one year at a price which may be lower that the Issue Price.
- Its may be unable to grow the company's business in additional geographic regions or international markets, which may adversely affect its business prospects and results of operations.
- The Company has experienced negative cash flow in the past and may continue to do so in the future, which could have a material adverse effect on its business, prospects, financial condition, cash flows and results of operations.
- The company is dependent on third party transportation providers for delivery of raw materials to it from its suppliers and delivery of the company finished products to its customers. The company has not entered into any formal contracts with its transport providers and any failure on part of such service providers to meet their obligations could adversely affect its business, financial condition and results of operation.
- The company has significant power requirements for continuous running of its manufacturing units. Any disruption to the company's operations on account of interruption in power supply or any irregular or significant hike in power tariffs may have an effect on its business, results of operations and financial condition.
- The company's Promoters, Directors, Senior Management and Key Managerial Personnel have interests in the Company other than reimbursement of expenses incurred or normal remuneration or benefits.
- Its Promoters, Directors and members of Promoter Group have extended personal guarantees with respect to loan facilities availed by the Company. Further, its Promoters have extended personal properties as collateral for securing the facilities availed by the Company. Revocation of any or all of these personal guarantees or withdrawal of such properties may adversely affect its business operations and financial condition.
- Its Promoters and members of the Promoter Group have significant control over the Company and have the ability to direct its business and affairs; their interests may conflict with your interests as a shareholder.
- The average cost of acquisition of Equity Shares held by its Promoters could be lower than the Issue Price.
- The company's future fund requirements, in the form of further issue of capital or securities and/or loans taken by it, may be prejudicial to the interest of the Shareholders depending upon the terms on which they are eventually raised.
- The company has in past entered into related party transactions and its may continue to do so in the future.
- Its agreements with lenders for financial arrangements contain restrictive covenants for certain activities and if the company is unable to get their approval, it might restrict its scope of activities and impede the company growth plans.
- The Company has availed certain unsecured loans from its Promoters and third parties, which are recallable in nature.
- In addition to its existing indebtedness for the company existing operations, its may incur further indebtedness during the course of business. The company cannot assure that its would be able to service its existing and/ or additional indebtedness.
- The company has not made any alternate arrangements for meeting its capital requirements for the Objects of the Issue. Further, the company has not identified any alternate source of financing the 'objects of the Issue'. Any short fall in raising / meeting the same could adversely affect its growth plans, operations and financial performance.
- If the company is unable to identify customer demand accurately and maintain an optimal level of inventory proportionately, its business, results of operations and financial condition may be adversely affected.
- The company's success largely depends upon the knowledge and experience of its Promoters, Directors and the company Key Managerial Personnel. Loss of any of its Directors and key managerial personnel or the company's ability to attract and retain them could adversely affect its business, operations and financial condition.
- The company's inability to procure and/or maintain adequate insurance cover in connection with its business may adversely affect the company's operations and profitability.
- Its ability to pay dividends in the future may be affected by any material adverse effect on its future earnings, financial condition or cash flows.
- The deployment of funds is entirely at its discretion and as per the details mentioned in the chapter titled "Objects of the Issue".
- The company has not independently verified certain data in this Draft Red Herring Prospectus.
- The requirements of being a listed company may strain its resources.
- Delay in raising funds from the IPO could adversely impact the implementation schedule.
- The Equity Shares have never been publicly traded and the Issue may not result in an active or liquid market for the Equity Shares.
- There is no guarantee that the Equity Shares issued pursuant to the Issue will be listed on the SME Platform of National Stock Exchange of India Limited in a timely manner or at all.
- There is no existing market for its Equity Shares, and the company does not know if one will develop to provide you with adequate liquidity. Further, an active trading market for the Equity Shares may not develop and the price of the Equity Shares may be volatile.
- Any variation in the utilisation of the Net Proceeds or in the terms of any contract as disclosed in the Draft Red Herring Prospectus would be subject to certain compliance requirements, including prior shareholders' approval.
- You will not be able to sell immediately on the Stock Exchanges any of the Equity Shares you purchase in the Issue.
- There are restrictions on daily movements in the trading price of the Equity Shares, which may adversely affect a shareholder's ability to sell Equity Shares or the price at which Equity Shares can be sold at a particular point in time.
- The price of the Equity Shares may be volatile, which could result in substantial losses for investors acquiring the Equity Shares in the Issue.
- Any future issuance of Equity Shares, or convertible securities or other equity-linked securities by the Company may dilute your shareholding and any sale of Equity Shares by its Promoters or members of the company's Promoter Group may adversely affect the trading price of the Equity Shares.
- Rights of shareholders under Indian laws may be more limited than under the laws of other jurisdictions.
The Issue type of Onyx Biotec Ltd is Book Building - SME.
The minimum application for shares of Onyx Biotec Ltd is 2000.
The total shares issue of Onyx Biotec Ltd is 4810000.
Initial public offer of upto 48,10,000 equity shares of face value of
Rs. 10/- each ("Equity Shares") of the company at an issue price of Rs. 61 per equity share (including a share premium of Rs. 51 per equity share) for cash, aggregating up to Rs. 29.34 crores ("Public Issue") out of which 2,44,000 equity shares of face value of Rs. 10/- each, at an issue price of Rs. 61 per equity share for cash, aggregating Rs. 1.49 crores will be reserved for subscription by the market maker to the issue (the "Market Maker Reservation Portion"). The public issue less market maker reservation portion i.e. issue of 45,66,000 equity shares of face value of Rs. 10/- each, at an issue price of Rs. 61 per equity share for cash, aggregating up to Rs. 27.85 crores is hereinafter referred to as the "Net Issue". The public issue and net issue will constitute 26.53 % and 25.18 % respectively of the post-issue paid-up equity share capital of the company.